Unknown

Dataset Information

0

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.


ABSTRACT: Galactose-deficient IgA1 was evaluated in patients with IgA nephropathy(IgAN) and controls in order to determine the predictive value of galactose-deficient IgA1 in cases of IgA nephropathy.PubMed, EMBASE, Cochrane central register of controlled trials, CNKI, CBM disc, and VIP database were searched to identify eligible studies that evaluated a difference in aberrant IgA1 glycosylation in IgAN patients compared with controls. A meta-analysis was conducted to evaluate the impact of galactose-deficient IgA1(Gd-IgA1) levels in different groups.A total of 22 studies (n = 1657) met inclusion criteria. The mean Newcastle-Ottawa Scale (NOS) score was 7.2 and ranged from 6 to 8. The standard mean difference(SMD) in the meta-analysis of 20 studies of the level of Gd-IgA1 in the serum and/or supernatant of cultured cells was higher in the IgAN group compared with healthy controls as well as in those with other renal diseases (SMD = 1.76, 95% CI = 1.18-2.34, P<0.00001; SMD = 1.05, 95% CI = 0.05-2.04, P = 0.04). The data synthesis suggested that IgAN patients had similar levels of serum Gd-IgA1, with no significant differences, compared with first-degree relatives and Henoch-Schonlein purpura nephritis (HSPN) patients (MD = 0.04, 95% CI = 0.00-0.08, P = 0.05; MD = -46.03, 95% CI = -217.70-125.64, P = 0.60). In addition, the combined MD of 5 studies indicated that there were no significant differences in Gd-IgA1 levels among patients with varying severities of IgAN (MD = 0.02, 95% CI = -0.02-0.05, P = 0.28).The pooled evidence suggests that the level of Gd-IgA1 in the serum or supernatant of cultured cells from peripheral blood or tonsils may be a useful biomarker for predicting IgA nephropathy, though the level of Gd-IgA1 was not significantly associated with disease severity.

SUBMITTER: Sun Q 

PROVIDER: S-EPMC5117702 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7260647 | BioStudies
2020-01-01 | S-EPMC7000803 | BioStudies
2016-01-01 | S-EPMC5018335 | BioStudies
2018-01-01 | S-EPMC6214568 | BioStudies
2014-01-01 | S-EPMC4032235 | BioStudies
2020-01-01 | S-EPMC7372907 | BioStudies
1000-01-01 | S-EPMC5461789 | BioStudies
2020-01-01 | S-EPMC7179927 | BioStudies
2011-01-01 | S-EPMC3641561 | BioStudies
2020-01-01 | S-EPMC7521275 | BioStudies